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Cytotoxic CD8T cells mediate immunity to pathogens and they are able to eliminate malig-
nant cells. Immunity to viruses and bacteria primarily involves CD8 T cells bearing high
affinity T cell receptors (TCRs), which are specific to pathogen-derived (non-self) antigens.
Given the thorough elimination of high affinity self/tumor-antigen reactiveT cells by central
and peripheral tolerance mechanisms, anti-cancer immunity mostly depends onTCRs with
intermediate-to-low affinity for self-antigens. Because of this, a promising novel therapeu-
tic approach to increase the efficacy of tumor-reactive T cells is to engineer their TCRs,
with the aim to enhance their binding kinetics to pMHC complexes, or to directly manipu-
late theTCR-signaling cascades. Such manipulations require a detailed knowledge on how
pMHC-TCR and co-receptors binding kinetics impact theT cell response. In this review, we
present the current knowledge in this field. We discuss future challenges in identifying and
targeting the molecular mechanisms to enhance the function of natural orTCR-affinity opti-
mized T cells, and we provide perspectives for the development of protective anti-tumor T
cell responses.
Keywords: cytotoxic T cells, TCR-affinity, melanoma, immunotherapy, TCR engineering, TCR signaling, T cell
activating receptors,T cell inhibitory receptors
QUANTITATIVE ASPECTS OF ANTIGEN RECOGNITION BY CD8
T LYMPHOCYTES
Cytotoxic CD8 T lymphocytes recognize through their T cell
receptors (TCRs) an antigenic peptide that is presented by MHC
class I molecules (peptide-MHC, pMHC) on the surface of an
infected or transformed cell. TCR triggering activates in T cells
a signaling cascade, which leads to the release of effector mole-
cules and to the cytolytic elimination of the cell that stimulated
the T cell. The efficiency of triggering a T cell response critically
depends on how well a TCR binds to a stimulating pMHC com-
plex and stronger interactions are thought to cause more vigorous
T cell activation than weaker interactions (Stone et al., 2009; Zehn
et al., 2009). The dissociation constant K D is a physical parameter
that is generally used to describe the strength with which a TCR
binds to a given pMHC complex (Zehn et al., 2012) and to which
we usually refer to as the affinity of TCR and pMHC interaction.
Peripheral CD8 T cells express TCRs that only weakly react
with self-peptide presenting pMHC and the K D values of these
interactions are in the range of 100–10µM (Cole et al., 2007).
In contrast, TCRs that interact with foreign-peptide presenting
MHC with a K D of up to 1µM are frequently found among
T cells that respond to pathogens (Davis et al., 1998). In fact,
it is well established that immune responses to pathogen are
dominated by cytotoxic T cells that express high affinity TCRs
(Figure 1), and these cells are thought to be superior in execut-
ing effector function than low affinity T cells (Speiser et al., 1992;
Alexander-Miller et al., 1996). Nonetheless, recent observations
indicate that also a larger number of lower affinity T cell clones
participate in immune responses. Moreover, it is well established
that anti-tumor immune responses critically rely on lower affin-
ity T cells, as most high affinity self/tumor-antigen specific T cells
are usually thoroughly eliminated by both central and peripheral
tolerance mechanisms. Within the subsequent sections, we will
present key findings regarding the biology of cytotoxic CD8 T cells
that respond with high or low affinity to antigen, we will describe
how differences in affinity impact the outcome of a T cell response,
and we will discuss several strategies to bypass the limitation that
are linked to T cell responses mediated by low affinity T cells.
EVIDENCE FOR THE PARTICIPATION OF LOW AFFINITY CD8 T
CELLS IN IMMUNE RESPONSES TO PATHOGENS
To characterize how TCR–pMHC affinity impacts T cells in an
infection, we expressed in pathogens a set of altered peptide lig-
ands that gradually differ in the strength of binding to the OT-1
TCR. By infecting mice with pathogens expressing these ligands,
we can mimic high, intermediate, or low affinity stimulation, as
it would be the case with polyclonal cytotoxic T cells of which
some respond with high and others with low affinity to pathogen-
derived antigen (Zehn et al., 2009). Unexpectedly, we found that
the OT-1 T cells initially responded similarly to pMHC complexes
that very differently stimulated the OT-1 TCR. Even very low affin-
ity complexes induced the same initial rapid T cell proliferation as
high affinity ones. Low affinity-stimulated OT-1 CD8 T cells were
early on phenotypically indistinguishable from cells stimulated by
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FIGURE 1 | Model integrating the relationship betweenT cell
responsiveness (e.g., cell signaling, gene expression, and functionality)
andTCR-affinity (in K D, µM) of human CD8T lymphocytes engineered
with anti-tumorTCR variants of optimized affinities (Irving et al., 2012;
Hebeisen et al., 2013; Zhong et al., 2013). Optimal/maximal T cell
effectiveness is observed with cells expressing affinities in the upper natural
limit (K D from 5 to 1µM; dark green). Negative regulation mechanisms may
counteract T cell responsiveness in T cells bearing very high affinities
(depicted as blue gradients) (Corse et al., 2010; Slansky and Jordan, 2010;
Hebeisen et al., 2013). Moreover, Zhong et al. (2013) recently described an
affinity threshold (K D around 10µM) for maximal anti-tumor activity and
autoreactivity (depicted as orange gradients).
high affinity complexes. Expression of effector molecules such as
granzyme B, as well as effector and memory T cell functions were
surprisingly efficient (Zehn and Bevan, 2006; Enouz et al., 2012). It
has also been shown that very low affinity stimulated T cells sup-
port pathogen elimination (Turner et al., 2008). Together, these
findings indicate that lower affinity CD8 T cells fully participate
in the immune response.
However, there is a major difference between low and high
affinity CD8 T cells. Namely, the former undergo fewer rounds
of division and decline in numbers faster than high affinity stim-
ulated T cells. Thus, while undergoing full differentiation, low
affinity primed effector T cells reach lower numbers. Therefore
the high affinity T cells dominate in numbers at the time when T
cell expansion is at its maximum.
Given their low numbers, one may question the importance
of low affinity CD8 T cells. The large numbers of high affinity T
cells at the peak of the immune response have so far distracted
from exploring the relevance of low affinity T cells during infec-
tion. Several kinetic aspects may suggest that low affinity T cells
could perhaps be more important than previously appreciated. In
the naïve T cell repertoire, high affinity T cell clones specific to
any given antigen are rare. In contrast, it is likely that low affinity
T cell clones are more frequent. As low and high affinity clones
expand equally at the beginning, there should be a larger number
of low than high affinity effector T cells in the early phase of the T
cell response, as we found in our experiments. The dominance of
high affinity CD8 T cells develops later, because these cells over-
grow the lower affinity T cells in the late T cell expansion phase
(Zehn et al., 2009). Importantly, we noticed that low affinity T
cells leave secondary lymphoid organs earlier than high affinity
T cells, suggesting that the earliest wave of effector T cells that
enter peripheral organs predominately consists of low affinity T
cells. Thus, the critical early phase of pathogen elimination may
be primarily achieved by low affinity cytolytic T cells (Zehn et al.,
2009).
The number of low affinity T cells responding to one particular
epitope is perhaps small. However, there could be many unknown
epitopes recognized by low affinity T cells, which cumulatively
might result in a reasonably sized T cell population. These consid-
erations suggest that low affinity CD8 T cells play a more important
role during infection than previously anticipated, which may have
been underestimated in the past.
ANTI-SELF AND -TUMOR IMMUNE RESPONSES ARE
FREQUENTLY MEDIATED BY LOW AFFINITY CD8 T CELLS
Anti-tumor immune response targets tumor-associated anti-
gens such as cancer testis antigens (e.g., NY-ESO-1 or MAGEs)
expressed by several tumors or differentiation antigens (e.g.,
Melan-A/MART-1, gp100, or tyrosinase) expressed in melanoma
cells (Romero et al., 2002; Van Der Bruggen et al., 2002; Boon et al.,
2006). Most of these antigens are expressed in the thymus (Kyewski
and Klein, 2006) and accordingly, T cells with high affinity become
negatively selected. As a backup, tumor-antigen reactive T cells can
be eliminated in the periphery through mechanisms of peripheral
tolerance (Kurts et al., 1997). However, it has been convincingly
shown, that these mechanisms spare cytotoxic T cells that react
with lower affinity to self- or tumor-antigens (von Herrath et al.,
1994; Zehn and Bevan, 2006; McMahan and Slansky, 2007; Turner
et al., 2008). Although, it is still often rather difficult to judge
how effectively lower affinity CD8 T cells execute effector T cell
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functions, several strong line of evidence indicate that low affin-
ity auto-reactive T cells are able to eliminate tumors and play a
critical role in autoimmunity (von Herrath et al., 1994; Zehn and
Bevan, 2006; McMahan and Slansky, 2007; Bulek et al., 2012). In
fact, it becomes more and more clear that most self/tumor-specific
cytotoxic T cells express low affinity TCRs and there is increasing
evidence that the self/tumor-specific T cells are indeed capable to
destroy cancer cells in vivo (Boon et al., 2006; Rosenberg et al.,
2008). Moreover, it has been shown that self/tumor-antigen spe-
cific CD8 T cells can undergo considerable clonal expansion in
cancer patients, differentiate to memory and effector cells, and
persist during several years at relatively high frequencies (Speiser
et al., 2011; Baitsch et al., 2012). These observations are well in
line with the aforementioned findings that low affinity CD8 T
cells participating in the response to pathogens may have great
implications for anti-cancer immunity.
However, researchers must still deal with several challenges
associated with activating low affinity CD8 T cells. For example,
these cells require higher numbers of presented pMHC complexes
than high affinity T cells before they become activated and for
mounting an effector T cell response. Also, requirements for inter-
actions with DCs by CD8 T cells of low TCR affinities are likely
higher, to achieve sufficient TCR triggering and co-stimulation
(Liechtenstein et al., 2012; Chen and Flies, 2013). Furthermore,
lower affinity CD8 T cells undergo, as mentioned above, shorter
clonal expansion following stimulation than high affinity T cells
which means that fewer of such cells will be obtained following
vaccination. Given these limitations, we need to find better ways
to more effectively activate these T cells, to enhance their function,
and to selectively interfere with the mechanisms, which prevent
these cells from responding to tumors. One possible way to do
this is to alter the kinetics with which the TCR of a tumor-specific
T cell binds to its peptide-pMHC complex. Another approach
would be to manipulate the signaling cascades downstream of
the TCR.
TCR-AFFINITY OPTIMIZATION AGAINST CANCER ANTIGENS
Immunotherapy aims at mobilizing the body’s immune cells to
fight against tumor cells in a highly specific manner. There are
two biological strategies to achieve immune activity: active immu-
nization with the use of vaccination and passive immunization.
A form of passive immunotherapy is the adoptive cell transfer
(ACT) of autologous T lymphocytes to patients with metasta-
tic cancer (Restifo et al., 2012). This approach uses autologous
TIL (tumor infiltrating lymphocytes), which are isolated from
metastatic lesions, expanded in vitro, and selected for tumor reac-
tivity. Remarkably, about 50 to 70% of patients with metastatic
melanoma experience objective clinical responses, and up to 20%
even have complete and durable responses (Rosenberg et al., 2011).
Nevertheless, further improvements are necessary.
A limiting factor is the relatively low affinity of tumor-antigen
reactive T cells. For improvement, T cells can be engineered with
TCRs of increased affinity for tumor-antigens before transfer to
patients (Figure 1). Indeed, this approach may augment the func-
tional and protective capacity of tumor-antigen reactive CD8 T
cells (Robbins et al., 2008, 2011; Bendle et al., 2009; Bowerman
et al., 2009; Chervin et al., 2009; Johnson et al., 2009). In turn,
TCR engineering also bears the risk that the normal tissue could
be harmed. It has been demonstrated that T cells, whose TCR
binds to pMHC complexes with very high affinities (K D < 1 nM)
lose antigen specificity and can become cross-reactive or allo-
reactive (Holler et al., 2003; Zhao et al., 2007; Robbins et al., 2008).
Importantly, genetically engineered T lymphocytes expressing very
high affinity self/tumor-specific TCRs also target normal tissues
expressing the cognate antigen (e.g., melanocytes in the skin, eye,
and ear for Melan-A-specific T cells and neurons for MAGE-
A3-specific T cells), and can mount harmful cytotoxic immune
responses in vivo (Johnson et al., 2009; Morgan et al., 2013). More-
over, TCR mispairing between introduced and endogenous TCR
α and β chains has also been shown to lead to off-target toxic-
ity (Bendle et al., 2010; van Loenen et al., 2010). Therefore, TCR
optimization through affinity alteration must include the evalua-
tion of optimal T cell responsiveness and lack of cross-reactivity
to ensure the safety of TCR-engineered T cells in clinical trials.
Moreover, it must further include the development of new strate-
gies to minimize the extent of mispairing (reviewed in Govers et al.,
2010; Daniel-Meshulam et al., 2012), as elegantly shown by Aggen
et al. (2012), describing the use of stabilized VαVβ single-chain
TCRs (scTv; Figure 2). Unfortunately, unexpected auto-reactive
responses may never be completely excluded. In that regard, it is
important to further study the tissue distribution of self/tumor-
antigen expression, to optimize the choice of antigens targeted by
ACT therapy (e.g., cancer testis versus differentiation antigens)
(Offringa, 2009).
TCR-AFFINITY THRESHOLD FOR MAXIMAL ANTI-TUMOR CD8
T CELL RESPONSE
During recent years we established a panel of human CD8 T
cells expressing engineered TCRs of optimized affinities against
the tumor-antigen NY-ESO-1 presented in the context of HLA-
A2. They were obtained through structure-based rational pre-
dictions (Zoete and Michielin, 2007; Zoete et al., 2010). The
functional potential of these T cells (Schmid et al., 2010; Irving
et al., 2012) showed that T cells expressing TCRs with affini-
ties in the upper natural range (K D from 5 to 1µM) displayed
greater biological responses when compared to those expressing
intermediate affinity wild-type TCR (K D at 21.4µM) or very low
affinity (K D > 100µM) (Figure 1). Unexpectedly, we noticed that
T cells which express TCRs beyond the natural affinity range
(K D < 1µM) showed a severe decline in their gene expression
profile, signaling, and functionality (Irving et al., 2012; Hebeisen
et al., 2013), despite retaining their antigen specificity and show-
ing no broad cross-reactivity as observed in other studies (Holler
et al., 2003). Major findings revealed that maximal T cell effec-
tiveness was limited by at least two mechanisms (Figure 1). The
first one was characterized by the preferential expression of the
inhibitory receptor programed cell death-1 (PD-1) within T cells
of the highest TCR affinities and this correlated in those cells
with full functional recovery upon PD-1 ligand 1 (PD-L1) block-
ade (Hebeisen et al., 2013). The second one contrasted to PD-1
expression with the gradual upregulation of the Src homology 2
domain-containing phosphatase 1 (SHP-1) in CD8 T cells with
increasing TCR affinities. Consequently, pharmacological inhi-
bition allowed further incremental gaining of cell function in
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FIGURE 2 | Overview of mechanisms and potential therapeutic
targets as a strategy to improve tumor-antigen reactiveT
lymphocytes. These include a large variety of receptors (e.g.,
engineered TCRs, activating/inhibitory surface receptors, cytokine
receptor) as well as TCR-downstream signaling molecules (e.g., SHP-1,
SHP-2, PP2A) that regulate T cell activation, signaling, and function
(e.g., killing, cytokine secretion) against cancer antigens. Of note, the
scTv single VαVβ chain TCRs may be linked to intracellular signaling
domains such as Lck and CD28, independently of the CD3 subunits
(Aggen et al., 2012).
all engineered T cells, according to their TCR-binding affinities
(Hebeisen et al., 2013).
Our observations provide new evidence that T cell activation
and signaling may be limited to a given affinity threshold for the
TCR-pMHC interaction and that above this threshold, T cells may
not develop productive functions. They also nicely fit with other
in vitro and in vivo studies that reported maximal T cell responses
at an optimal TCR–pMHC off rate (koff) or K D while functional
attenuation was observed when kinetic parameters extended above
the natural range (Kalergis et al., 2001; Gonzalez et al., 2005;
McMahan et al., 2006; Carreno et al., 2007; Corse et al., 2010;
Thomas et al., 2011). Furthermore, Krogsgaard and colleagues
(Zhong et al., 2013) recently evaluated the TCR-affinity threshold
defining the optimal balance between effective anti-tumor activity
and autoimmunity in vivo, using human melanoma gp100209-217 –
specific TCRs spanning within the physiological affinity range.
Their results show the presence of an affinity threshold (around
10µM) for maximal anti-tumoral activity and autoreactivity, sug-
gesting that a relatively low-affinity threshold is necessary for
the immune system to avoid self-damage (Zhong et al., 2013).
Altogether, we and others propose that the rational design of
improved self-specific TCRs for adoptive T cell therapy may not
need to be optimized beyond the natural TCR-affinity range to
achieve optimal T cell function and avoidance of unpredictable
risk of cross-reactivity (Schmid et al., 2010; Slansky and Jordan,
2010).
Recently, Liddy et al. (2012) described the use of novel reagents
termed immune-mobilizing monoclonal TCRs (or ImmTACs)
against tumor-antigens including NY-ESO-1, which are fused to a
humanized CD3-specific single-chain αβ fragment (scFv). These
ImmTACs comprise TCRs of picomolar affinity range and allow
to effectively redirect T cells to kill in vivo cancer cells expressing
very low surface epitope densities. In line with previous studies
from the same group (Li et al., 2005; Dunn et al., 2006), soluble
monomeric TCRs possessing affinity≈106-fold higher than native
TCRs showed a remarkable high degree of specificity for the cog-
nate pMHC molecules. Possibly, soluble monomeric TCRs may
allow circumventing the two major limitations associated with
TCR engineering within CD8 T cells. First, the loss of target cell
specificity associated with T cells expressing extremely high affin-
ity TCRs (K D < 1 nM) (Zhao et al., 2007; Robbins et al., 2008).
And second, the functional defects of T cells with supraphysiolog-
ical TCR affinities (K D < 1µM) (Kalergis et al., 2001; Gonzalez
et al., 2005; McMahan et al., 2006; Corse et al., 2010; Thomas et al.,
2011).
At present, what remains intriguing is how super affine TCRs
modulate cell activation and responsiveness. One likely expla-
nation is that in contrast to soluble TCRs, the cellular TCR
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expression integrates and potentiates the effect of several vari-
ables/parameters including TCR density, multivalent TCR cluster-
ing, and basal cell activation state (Stone et al., 2009). Furthermore,
several observations including ours (Hebeisen et al., 2013) now
indicate that T cell activation and signaling is also finely tuned
by the proximal TCR-signaling complex as well as by activa-
tory or inhibitory co-receptors, and will be discussed in detail
below.
LOW AND HIGH AFFINITY ANTIGEN RECOGNITION DEPENDS
ON THE PROXIMAL TCR-SIGNALING COMPLEX
The TCR complex is composed of the TCR αβ chains, which
are directly involved in the pMHC recognition, and of the
invariant CD3 proteins, that contain in their cytosolic domains
the immunoreceptor tyrosine-based activation motifs (ITAM)
(Hedrick et al., 1984; Malissen et al., 1984; Letourneur and Klaus-
ner, 1992). TCR triggering elicits a series of membrane-associated
events, leading to the transduction of signal across the plasma
membrane and phosphorylation of key residues in the TCR-
associated CD3 ITAM domains (Stefanova et al., 2003; James and
Vale, 2012). Phosphorylation of CD3ζ-associated ITAM is medi-
ated by the Src family kinases Lck and Fyn (Acuto et al., 2008)
and form docking sites for several protein tyrosine kinases (PTKs)
including the Syk-family kinase ζ-associated protein of 70 kDa,
ZAP-70. Activation of ZAP-70 by Lck in turns results in phos-
phorylation and activation of other proteins and recruitment of
adaptors (e.g., LAT and SLP-76). This initiates the formation of
multi-molecular signalosomes, leading to the subsequent gener-
ation of secondary messengers and of multiple distal signaling
cascades (Acuto et al., 2008; Smith-Garvin et al., 2009).
CD8 T cells may further adapt these signaling pathways to dif-
ferent stimulation conditions and different requirements for anti-
gen sensitivity. Several lines of evidence indicate that differential
patterns of CD3ζ ITAM phosphorylation directly modulate TCR-
pMHC mediated downstream signaling and that ITAMs can act as
both positive (ITAMs) and negative (inhibitory ITAMi) cell signal-
ing regulators (Blank et al., 2009). For instance, resting peripheral
T cells have a constitutive pattern of phosphorylated ITAMs, and
incomplete CD3ζ ITAM phosphorylation after TCR triggering can
by itself become inhibitory depending on the nature of the TCR
ligand (Kersh et al., 1999). Thus, it is of great importance to fur-
ther explore whether distinct CD3ζ ITAM phosphorylation states
could also influence cell activation and responsiveness along the
range of TCR-affinity and particularly in engineered CD8 T cells
of supraphysiological affinity TCRs.
Lck represents another key regulatory element involved in the
modulation of proximal TCR activation and signaling, and Lck
activation stage may currently be viewed as a sensor of the strength
of TCR engagement. On the one hand, weak binding of the
TCR triggers Lck-dependent activation and recruitment of SHP-1,
which in a classical feedback loop inactivates Lck and downregu-
lates TCR signaling. On the other hand, stronger TCR activation
induces an Erk-dependent Lck phosphorylation that impairs the
inhibitory SHP-1 recruitment and in contrast reinforces TCR sig-
naling by decreasing the threshold of T cell activation (Stefanova
et al., 2003). Interestingly, as mentioned above, we recently used
a panel of CD8 T cells engineered with TCRs of incremental
affinities for an NY-ESO-1 derived peptide and saw that SHP-1
phosphatase was upregulated in a TCR-affinity-dependent man-
ner, with the highest levels in T cells of the supraphysiological
TCRs (Hebeisen et al., 2013). These observations further suggests
that SHP-1 may play a dual role and restricts not only T cell sig-
naling at the very low range of TCR stimulation (e.g., antagonist
ligands) as described by Stefanova et al. (2003), but also at the
higher range.
Other phosphatases have been shown to act on the proximal
TCR signaling such as Lyp, a PTPN22 encoded phosphatase, and
together with Csk inhibit T cell activation, likely through dephos-
phorylation of the activating tyrosine on Lck and ZAP-70 (Cloutier
and Veillette, 1999). The importance of PTPN22 is highlighted by
the observation that PTPN22 deficient mice have augmented TCR-
induced phosphorylation and activation (Hasegawa et al., 2004).
Furthermore, a point mutation in PTPN22 has been found asso-
ciated with several autoimmune diseases (Mustelin et al., 2005).
The precise role of PTPN22 in T cell activation remains unknown
and there is contradictory data on the effect of the polymorphism
found in autoimmune patients and whether or not it causes a loss
or gain of function (Vang et al., 2005).
These TCR-affinity-dependent feedback mechanisms are likely
part of a tunable instrument that enables T cells to adapt their reac-
tivity to different stimulatory conditions, and we have just began
to understand how those are achieved. For instance specific micro-
RNAs such as miR-181a are thought to be critical in augmenting
TCR-signaling sensitivity during positive selection in the thymus
(Li et al., 2007). The expression of miR-181a has been shown
to decrease the amount of several phosphatases, resulting in an
elevated steady-state level of phosphorylated proteins of the TCR-
signaling cascade and therefore a reduction in the TCR-signaling
threshold (Li et al., 2007; Ebert et al., 2009). TCR activation and
signaling transduction may also be negatively regulated by SHP-1
phosphatase and contributes to the settings of threshold during
thymocyte selection (Plas et al., 1996; Acuto et al., 2008). More-
over, SHP-1 and SHP-2 can be recruited by multiple inhibitory
surface receptors in T cells, and inhibit TCR signaling through
dephosphorylation of proximal targets including Lck and ZAP-70
(Lorenz, 2009). In line with this concept, Yokosuka et al. (2012)
recently showed that ITIM-containing PD-1 could directly inhibit
TCR-mediated signaling by recruiting SHP-2 phosphatase in a
TCR stimulation strength-dependent manner.
CYTOTOXIC CD8 T CELL RESPONSES ARE REGULATED BY
ACTIVATING AND INHIBITORY SURFACE RECEPTORS
Co-stimulatory and inhibitory membrane receptors have great
influence on T cell responses (Chen and Flies, 2013). T cell co-
stimulation prevents T cell anergy, a state of unresponsiveness
that is induced after TCR stimulation in absence of co-stimulation
(Figure 2). This was first observed when studying co-stimulation
via CD28 that binds to its ligands B7.1 (CD80) and B7.2 (CD86)
expressed on antigen-presenting cells (APC). This interaction also
lowers the threshold for T cell activation, thus allowing increased
IL-2 production and promoting cell proliferation and survival
(Sharpe and Freeman, 2002). CD28 ligation stimulates T cell func-
tion by activating phosphoinositol-3-kinase (PI3K) and protein
kinase C theta (PKCθ), and the downstream Akt, mTOR, and Ras
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signaling pathways, which eventually synergize with TCR signaling
(Smith-Garvin et al., 2009). T cell activation also leads to surface
expression of CTLA-4, which has a much higher binding avidity to
B7.1 and B7.2, and thus outcompetes CD28 (Greene et al., 1996).
Possibly, this may be the main reason for CTLA-4 mediated T cell
inhibition. In addition, it has been shown that CTLA-4 directly
triggers inhibitory signaling by interacting with SHP-1, SHP-2,
and PP2A phosphatases, with the consequence of down-regulating
TCR-signaling pathway (Scalapino and Daikh, 2008). CTLA-4
inhibition also occurs indirectly via retro-signaling through B7.1
and B7.2 and production of IDO in APCs (Grohmann et al.,
2002) or by a process of trans-endocytosis of its ligands (B7.1
and B7.2) from APC (Qureshi et al., 2011). CTLA-4 may prefer-
entially inhibit T cells with strong TCR signaling, as suggested by
observations that accumulation of CTLA-4 at the immunological
synapse depended on the strength of TCR triggering (Egen et al.,
2002).
Programed death-1 is also highly upregulated in T cells fol-
lowing TCR stimulation, similarly to CTLA-4. Expression of
PD-1 is not restricted to T cells, suggesting a broader role in
immune regulation (Greenwald et al., 2005). PD-1 interacts with
the two ligands PD-L1 and PD-L2, expressed non-redundantly
in different tissues and cell types. CTLA-4-deficient mice have
lymphoproliferative disorders and early fatal multi-organ tis-
sue destruction (Tivol et al., 1995; Waterhouse et al., 1995),
whereas PD-1-deficient mice spontaneously develop milder forms
of autoimmune diseases (Nishimura et al., 2001). Based on the
observed differential expression of CTLA-4 and PD-1 ligands,
it is assumed that CTLA-4 plays a preferential role in limit-
ing T cell function early during thymocyte development and in
secondary lymphoid structures, whereas PD-1 may mediate inhi-
bition in the periphery, for example in maintaining long-term
peripheral tolerance to self-antigens by preventing activation of
self-reactive T cells that have escaped negative selection (Fife and
Pauken, 2011). TCR down-modulation through TCR/CD28 sig-
naling transduction represents a fundamental process regulating
the initial events of T cell activation. Recently, the interaction
of PD-L1 on DCs and PD-1 on CD8 T cells has been shown to
contribute to ligand-induced TCR down-modulation (Karwacz
et al., 2011). Furthermore, interference with PD-L1/PD-1 signal-
ing inhibited TCR down-modulation, leading to hyper-activated
and proliferative CD8 T cells in an arthritis model (Karwacz et al.,
2011).
In humans, a regulatory polymorphism in PD-1 is associated
with susceptibility to systemic lupus erythematosus and multi-
ple sclerosis (Prokunina et al., 2002; Kroner et al., 2005), while
polymorphisms of the CTLA-4 have been linked to multiple
autoimmune diseases including asthma, systemic lupus erythe-
matosus, Graves’ disease, and autoimmune thyroid diseases (Kris-
tiansen et al., 2000). The induction of PD-L1 ligand expression
was observed in several tumor cells as a mechanism of cancer
immune evasion (Schreiber et al., 2011). A specific polymorphism
of CTLA-4 was found to be protective for autoimmune disease,
but associated with risk of multiple types of cancer (Sun et al.,
2009).
Members of the tumor necrosis factor receptor (TNFR) super-
family represent further important co-stimulatory molecules,
mediating survival signals to T cells after initial CD28-B7 inter-
actions (Acuto and Michel, 2003) (Figure 2). Multiple members
of TNFR/TNF ligand pairs have been shown to directly impact
T cell function following TCR activation, namely OX40/OX40L,
4-1BB/4-1BBL, GITR/GITRL, CD27/CD70, and CD30/CD30L
(Watts, 2005). These receptors and their ligands are expressed on
a variety of immune and non-immune cells and are inducible
and non-ubiquitous, suggesting that they are involved in modu-
lating and coordinating global immune responses (Croft, 2009).
Intense translational and clinical research in this field aims at
modulating T cell function in pathological settings such as autoim-
munity and cancer (Figure 2). TNFR/TNF family member lig-
ation often induces bi-directional activating signaling pathways
in both the APC and the T cell. The recruitment of TNFR-
associated factors (TRAF) activate the NF-κB signaling path-
way and increase the expression of anti-apoptotic molecules,
thus promoting the survival of CD4 and CD8 T cells (Croft,
2009). Like CD28, TNFR signaling can also synergize with the
TCR pathway to promote cell cycle progression and cytokine
production. Finally, ligation of OX40 and 4-1BB may con-
comitantly block the generation of inducible regulatory T cells
(Tregs), and may inhibit their suppressive activity (So et al.,
2008).
A particularly unique and interesting member of the TNFR
superfamily is HVEM (Herpes virus entry molecule). It binds
to the TNFR ligands LIGHT and lymphotoxin Ltα3, which are
predominantly co-stimulatory and pro-inflammatory in T cells.
Curiously, HVEM also binds to BTLA and CD160, which are
structurally similar to PD-1 and CTLA-4 and transduce inhibitory
signals, in part through recruitment of SHP-1 and SHP-2 phos-
phatases (Watanabe et al., 2003; Sedy et al., 2005). The individ-
ual effects of HVEM interaction with its different ligands are
particularly complex to elucidate since both receptor and lig-
ands can be expressed on the same T cell, as well as on other
immune and epithelial cell types (Shui et al., 2011). Hvem−/−
and Btla−/− T cells were found to be hyper-responsive to TCR
stimulation in vitro. Furthermore, Hvem−/− and Btla−/− knock-
out mice had enhanced susceptibility to autoimmune diseases,
suggesting a predominant inhibitory role in T cells during inflam-
matory conditions (Watanabe et al., 2003; Wang et al., 2005). BTLA
was found to inhibit tumor-antigen specific cytotoxic T cells in
melanoma patients (Derre et al., 2010). HVEM may also inter-
act in cis with BTLA expressed by the same cell, likely interfering
with HVEM activation by other ligands (Ware and Sedy, 2011).
Therefore HVEM seems to mediate immune stimulation or inhibi-
tion in a switch-like, bi-directional, and context-dependent mode,
suggesting that HVEM/LIGHT/CD160/BTLA interactions repre-
sent an important regulatory network for controlling immune
responses.
Together, combined TCR and CD28/TNFR triggering primes
CD8 T cells, followed by positive and negative regulation. The lat-
ter involves CTLA-4, PD-1, and BTLA. This highlights the intricate
regulatory network that controls the immune system in health and
disease (Figure 2). These mechanisms can be exploited therapeu-
tically in patients with infectious or malignant diseases, as well as
in autoimmunity and transplantation (Fife and Bluestone, 2008;
del Rio et al., 2010).
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ACTIVATORY OR INHIBITORY T CELL SIGNALS MAY BE
TARGETED FOR THERAPEUTIC IMPROVEMENTS OF CANCER
THERAPIES
Since cytotoxic CD8 T cells and T-helper type 1 [Th1] cells have
the potential to eliminate cancer cells and to mediate long-term
protection from disease (Sallusto et al., 2010), it is important
to increase the functions of these anti-cancer T cells in cancer
patients. As mentioned above, basic immunology characterized a
number of interesting pathways that can be targeted to enhance
the performance of tumor-specific CD8 T cells. Some approaches
have already reached clinical application, but most still need to be
tested in clinical trials. The therapy that seems most efficient for
melanoma patients is the adoptive transfer of autologous tumor-
antigen specific T cells (Rosenberg, 2011). Molecular modification
of T cells before transfer may eventually increase the clinical effi-
cacy, despite that this is currently not the case (Speiser, 2013).
Several small-scale clinical studies suggested clinical usefulness of
inserting TCRs (Rosenberg, 2011) or chimeric antigen receptors
(Porter et al., 2011; Kochenderfer and Rosenberg, 2013). Hope-
fully, larger patient numbers will soon benefit thanks to steady
improvements of these techniques (Thomas et al., 2010; Di Stasi
et al., 2011; Linnemann et al., 2011; Ochi et al., 2011).
Not only antigen receptors but also co-receptors can be targeted
therapeutically (Figure 2). Receptors that inhibit T cell functions
are particularly attractive. Ipilimumab (Yervoy ®) is a mono-
clonal antibody that blocks the inhibitory receptor CTLA-4. It was
recently approved for the treatment of metastatic melanoma, as
it improves the clinical outcome, likely due to enhanced numbers
and functions of tumor-specific T cells (Hodi et al., 2010). More
recently, remarkable benefit for patients with advanced kidney
cancer, non-small-cell lung cancer, and melanoma (Ribas, 2012)
was demonstrated due to treatment with antibodies against PD-1
(Topalian et al., 2012) or its ligand PD-L1 (Brahmer et al., 2012).
Likely, these results represent real therapeutic progress, despite sig-
nificant toxicity linked to autoimmune reactions. Also, antibodies
that block LAG-3, TIM-3, B7-H3, or B7-H4 are under develop-
ment (Pardoll, 2012). Certainly, the clinical oncology landscape
will change during the next years due to these novel approaches.
In addition to the targeting of cell surface receptors, intracel-
lular mechanisms may be considered. In the complex signaling
network downstream of the TCR, there are several possibilities.
Interventions are for example possible at the level of E3 ligases
(Hoyne, 2011) (Figure 2). As therapeutic targets, the SHP pro-
tein tyrosine phosphatases have been proposed (Irandoust et al.,
2009). A member of a new class of SHP-1 inhibitors is the tyrosine
phosphatase inhibitor-1 (TPI-1) that has been shown to inhibit the
growth of transplanted tumor cells in mice together with enhanced
cytokine production by T cells (Kundu et al., 2010). However, opti-
mal targeting is challenged by the fact that SHP-1 and many other
signal transducers are widely expressed. For example, hematopoi-
etic tumors are suppressed by SHP-1 (Lopez-Ruiz et al., 2011), thus
precluding this approach for such diseases. Therefore, novel drugs
are needed that promote TCR signaling more specifically, suggest-
ing a drug development similar to what is pursued for optimizing
the well known tyrosine kinase inhibitors (De Roock et al., 2011;
Goldstraw et al., 2011; Cascone and Heymach, 2012). In parallel
to approaches targeting TCR pathways, further immune cells and
functions can be supported therapeutically, such as e.g., B cells,
adhesion- and homing-receptors, or cytokines (Scott et al., 2010;
Miller and Rhoades, 2012; Nylander and Hafler, 2012).
Most likely, we are only at the beginning of understanding
the enormous potential that is associated with the therapeutic
approaches discussed here. Significant progress is yet to come,
despite that immunotherapy has already become standard ther-
apy for some cancer patients. Besides, antibodies blocking CTLA,
anti-PD-1, and anti-PD-L1 mAb treatments and adoptive T cell
therapy are promising. Novel therapies need to be improved and
validated. Furthermore, it is important to learn predicting which
therapy is most suitable for which patient. Potentially predictive
parameters are the frequencies of tumor-reactive T cells, their abil-
ity to migrate to tumor sites, their affinity for antigen recognition,
status of effector function, and presence of inhibitory regulatory
circuits. More precise knowledge on correlates of protection, and
immune monitoring techniques for their characterization in indi-
vidual patients will support the progress of T cell based therapy
against cancer.
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